Novartis India Limited

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-25 am EDT			5-day change	1st Jan Change
1,046 ^INR	+1.92%		+1.12%	+35.26%

Apr. 01	Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	CI
Mar. 22	Novartis Eyes Sale of Listed Unit in India	CI

Novartis India Limited Appoints Nikhil Malpani as Company Secretary and Key Managerial Personnel

April 27, 2022 at 08:13 am EDT

The Board of Directors of the Novartis India Limited at its meeting held on April 27, 2022 has approved the appointment of Mr. Nikhil Malpani as the Company Secretary and Key Managerial Personnel of the Company with an immediate effect.

Latest news about Novartis India Limited

Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024	Apr. 01	CI
Novartis Eyes Sale of Listed Unit in India	Mar. 22	CI
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Swiss Market Index Closes in the Green on Healthcare Stocks Boost	Feb. 19	MT
Novartis Launches Strategic Review of Listed Indian Business	Feb. 19	MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India	Feb. 19	CI
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm	Feb. 17	CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18	Feb. 17	RE
Novartis India Limited Announces Completion of Tenure of Jai Hiremath as Independent Director, Effective March 31, 2024	Feb. 17	CI
Novartis AG Announces A Strategic Review of India Unit	Feb. 16	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Managing Director, Effective April 02, 2024	Jan. 25	CI
Novartis India Limited Announces Resignation of Mr. Sanjay Murdeshwar as Vice-Chairman, Effective April 02, 2024	Jan. 25	CI
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 25	CI
Novartis India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	23-10-26	CI
Novartis India Limited Announces Change in Registered Office Address	23-09-15	CI
Novartis India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-26	CI
Novartis India Limited Proposes One-Time Special Dividend	23-06-30	CI
Pfizer's India unit posts 3% rise in Q4 profit	23-05-15	RE
Novartis India Limited Recommends One-Time Special Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2023, Payable on or After August 2, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-10	CI
Novartis India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI
Novartis India Board to Consider Interim Dividend for Fiscal 2023	23-03-06	MT
Novartis India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-08	CI
Novartis India Limited Announces Board Changes	22-11-09	CI

Chart Novartis India Limited

Duration

Period

More charts

Company Profile

Novartis India Limited is an India-based company that is engaged in the business of trading of pharmaceuticals. The Company's portfolio of medicines addresses various therapeutic needs, such as cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India. In the bone and pain therapeutic area its brand is Voveran. In the transplantation immunology therapeutic area, the Company's brands include Simulect, Certican, Sandimmun, Neoral and Myfortic. In the neurosciences therapeutic area, its brands include Tegrital and Exelon.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS INDIA LIMITED	+35.26%	304M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.45%	358B
MERCK & CO., INC.	+19.12%	322B
ABBVIE INC.	+7.61%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.56%	149B
AMGEN INC.	-6.88%	146B